Načítá se...
Definition and management of ruxolitinib treatment failure in myelofibrosis
Ruxolitinib, a Janus kinase (JAK)-1 and JAK-2 inhibitor, is the first-in-class drug to be licensed in the United States for the treatment of high- and intermediate-risk myelofibrosis (MF). Several other JAK inhibitors are in development with some currently undergoing phase-3 clinical trial testing....
Uloženo v:
| Vydáno v: | Blood Cancer J |
|---|---|
| Hlavní autoři: | , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Nature Publishing Group
2014
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4315890/ https://ncbi.nlm.nih.gov/pubmed/25501025 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bcj.2014.84 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|